1. Home
  2. ICD-10-CM MS-DRG V42.0
  3. Diagnosis Codes in MS-DRG 839 - Chemotherapy With Acute Leukemia As Secondary Diagnosis Without CC/MCC

Diagnosis Codes in MS-DRG 839 - Chemotherapy With Acute Leukemia As Secondary Diagnosis Without CC/MCC

The Medicare Severity Diagnosis-Related Group or MS-DRG is a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). This is the group for Diagnosis Codes in MS-DRG 839 - Chemotherapy With Acute Leukemia As Secondary Diagnosis Without Complication Comorbidity/Major Complication or Comorbidity diseases in version MS-DRG V42.0 applicable from 10/01/2024 through 09/30/2025.

MS-DRG MS-DRG Title MCD Relative Weight Geometric LOS Arithmetic LOS
839 Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC 17 1.3703 Relative Weight
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization. 		1.37 Geometric Length of Stay
The geometric mean length of stay (GMLOS) is used by Medicare to calculate the reimbursement for patients whose medical treatment takes a much longer or shorter time than average. 		3.90 Arithmetic Length of Stay
The average length of stay (ALOS) reflects the average number of days a patient spends in a hospital for each admission.

List of ICD-10-CM Codes in Diagnostic Related Group


  • C91.0
    • C91.00 Acute lymphoblastic leukemia not having achieved remission
    • C91.01 Acute lymphoblastic leukemia, in remission
    • C91.02 Acute lymphoblastic leukemia, in relapse
  • C92.0
    • C92.00 Acute myeloblastic leukemia, not having achieved remission
    • C92.01 Acute myeloblastic leukemia, in remission
    • C92.02 Acute myeloblastic leukemia, in relapse
  • C92.4
    • C92.40 Acute promyelocytic leukemia, not having achieved remission
    • C92.41 Acute promyelocytic leukemia, in remission
    • C92.42 Acute promyelocytic leukemia, in relapse
  • C92.5
    • C92.50 Acute myelomonocytic leukemia, not having achieved remission
    • C92.51 Acute myelomonocytic leukemia, in remission
    • C92.52 Acute myelomonocytic leukemia, in relapse
  • C92.6
    • C92.60 Acute myeloid leukemia with 11q23-abnormality not having achieved remission
    • C92.61 Acute myeloid leukemia with 11q23-abnormality in remission
    • C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse
  • C92.A
    • C92.A0 Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
    • C92.A1 Acute myeloid leukemia with multilineage dysplasia, in remission
    • C92.A2 Acute myeloid leukemia with multilineage dysplasia, in relapse
  • C93.0
    • C93.00 Acute monoblastic/monocytic leukemia, not having achieved remission
    • C93.01 Acute monoblastic/monocytic leukemia, in remission
    • C93.02 Acute monoblastic/monocytic leukemia, in relapse
  • C94.0
    • C94.00 Acute erythroid leukemia, not having achieved remission
    • C94.01 Acute erythroid leukemia, in remission
    • C94.02 Acute erythroid leukemia, in relapse
  • C94.2
    • C94.20 Acute megakaryoblastic leukemia not having achieved remission
    • C94.21 Acute megakaryoblastic leukemia, in remission
    • C94.22 Acute megakaryoblastic leukemia, in relapse
  • C94.4
    • C94.40 Acute panmyelosis with myelofibrosis not having achieved remission
    • C94.41 Acute panmyelosis with myelofibrosis, in remission
    • C94.42 Acute panmyelosis with myelofibrosis, in relapse
  • C95.0
    • C95.00 Acute leukemia of unspecified cell type not having achieved remission
    • C95.01 Acute leukemia of unspecified cell type, in remission
    • C95.02 Acute leukemia of unspecified cell type, in relapse
    • Z08 Encounter for follow-up examination after completed treatment for malignant neoplasm
  • Z51.1
    • Z51.11 Encounter for antineoplastic chemotherapy
    • Z51.12 Encounter for antineoplastic immunotherapy